Search

Your search keyword '"Console, G."' showing total 170 results
Start Over Author "Console, G."

Refine your results

170 results on '"Console, G."'

7. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT: PH-P109

Author

Cattina, F., Skert, C., Bernardi, S., Malagola, M., Ottaviani, E., Bochicchio, M. T., Iacobucci, I., Soverini, S., Bonifazi, F., Bandini, G., Arpinati, M., Motta, M. R., Toffoletti, E., Damiani, D., Santoro, A., Fabbiano, F., Pastore, D., Specchia, G., Console, G., Bruno, M., Carella, G., Malagoli, A., Guadagnuolo, V., De Benedittis, C., Bergonzi, C., Filì, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, S., Di Palma, A., Martinelli, G., and Russo, D.

Published
2014

20. Non-myeloablative allogeneic stem cell transplantation in patients with high-risk lymphoma: a multicentre experience: R1287

Author

Console, G., Irrera, G., Martino, M., Messina, G., Pucci, G., Moscato, T., Fedele, R., Massara, E., Cuzzola, M., Pontari, A., Callea, I., Dattola, A., Garreffa, C., Spiniello, E., Meliadò, A., Rigolino, C., Del Vecchio, T., Iacopino, O., Cannatà, M. C., Scaramozzino, P., Bova, I., Marcuccio, D., Stelitano, C., Molica, S., Cantaffa, R., Nocilli, L., Mele, A., Pavone, V., Abbadessa, A., and Iacopino, P.

Published
2009

24. Radioimmunotherapy with haemopoietic stem cell transplantation for treatment of malignant non-Hodgkin lymphoma: multicentre study on thirty patients

Author

Mele, A., Rana, A., De Francesco, R., Del Casale, C., Messa, A., Greco, G., Sibilla, S., Frusciante, V., Varraso, A., Milone, G., Leotta, S., Olivieri, A., Ciminiello, M., Mettivier, V., Pezzullo, L., Musso, M., Porretto, F., Iacopino, P., Console, G., Cascavilla, N., Scalzulli, P., Musto, P., Caputo, M., Ostuni, A., and Pavone, V.

Published
2008

29. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs

Author

Pastore, D., Bruno, B., Carluccio, P., De Candia, M. S., Mammoliti, S., Borghero, C., Chierichini, A., Pavan, F., Casini, M., Pini, M., Nassi, L., Greco, R., Tambaro, F. P., Stefanoni, P., Console, G., Marchesi, F., Facchini, L., Mussetti, A., Cimminiello, M., Saglio, F., Vincenti, D., Falcioni, S., Chiusolo, Patrizia, Olivieri, J., Natale, A., Faraci, M., Cesaro, S., Marotta, S., Proia, A., Donnini, I., Caravelli, D., Zuffa, E., Iori, A. P., Soncini, E., Bozzoli, V., Pisapia, G., Scalone, R., Villani, O., Prete, A., Ferrari, A., Menconi, M., Mancini, G., Gigli, F., Gargiulo, G., Patriarca, F., Bonifazi, F., Chiusolo P. (ORCID:0000-0002-1355-1587), Pastore, D., Bruno, B., Carluccio, P., De Candia, M. S., Mammoliti, S., Borghero, C., Chierichini, A., Pavan, F., Casini, M., Pini, M., Nassi, L., Greco, R., Tambaro, F. P., Stefanoni, P., Console, G., Marchesi, F., Facchini, L., Mussetti, A., Cimminiello, M., Saglio, F., Vincenti, D., Falcioni, S., Chiusolo, Patrizia, Olivieri, J., Natale, A., Faraci, M., Cesaro, S., Marotta, S., Proia, A., Donnini, I., Caravelli, D., Zuffa, E., Iori, A. P., Soncini, E., Bozzoli, V., Pisapia, G., Scalone, R., Villani, O., Prete, A., Ferrari, A., Menconi, M., Mancini, G., Gigli, F., Gargiulo, G., Patriarca, F., Bonifazi, F., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT. The multicenter survey was performed by a questionnaire, covering the main areas on chemotherapy-induced nausea and vomiting (CINV): antiemetic prophylaxis guidelines used, antiemetic prophylaxis in different conditioning regimens, and methods of CINV evaluation. The survey was carried out in November 2016, and it was repeated 6 months after the publication of the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) specific guidelines on antiemetic prophylaxis in HSCT. The results show a remarkable heterogeneity of prophylaxis among the various centers and a significant difference between the guidelines and the clinical practice. In the main conditioning regimens, the combination of a serotonin3 receptor antagonist (5-HT3-RA) with dexamethasone and neurokin1 receptor antagonist (NK1-RA), as recommended by MASCC/ESMO guidelines, increased from 0 to 15% (before the publication of the guidelines) to 9–30% (after the publication of the guidelines). This study shows a lack of compliance with specific antiemetic guidelines, resulting mainly in under-prophylaxis. Concerted strategies are required to improve the current CINV prophylaxis, to draft shared common guidelines, and to increase the knowledge and the adherence to the current recommendations for CINV prophylaxis in the specific field of HSCT.

Published
2020

38. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study

Author

Martino, M, Montanari, M, Ferrara, F, Ciceri, F, Scortechini, I, Palmieri, S, Marktel, S, Cimminiello, M, Messina, G, Irrera, G, Offidani, M, Console, G, Castagna, L, Milone, G, Bruno, Benedetto, Tripepi, G, Lemoli, Rm, Olivieri, A, Terapia Cellulare – Sezione Trapianto Autologo, Gruppo Italiano per il Trapianto di Midollo Osseo Cellule Staminali Emopoietiche e., Saglio, Giuseppe, Martino, M, Montanari, M, Ferrara, F, Ciceri, Fabio, Scortechini, I, Palmieri, S, Marktel, S, Cimminiello, M, Messina, G, Irrera, G, Offidani, M, Console, G, Castagna, L, Milone, G, Bruno, B, Tripepi, G, Lemoli, Rm, and Olivieri, A.

Subjects
Adult, Male, medicine.medical_specialty, Autologous stem cell transplantation, Patient Readmission, Transplantation, Autologous, Autologous stem-cell transplantation, Multiple myeloma, Internal medicine, Outpatients, medicine, Mucositis, Early discharge model, Humans, Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) survey, Aged, Retrospective Studies, Univariate analysis, Transplantation, business.industry, Incidence (epidemiology), Outpatient, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Surgery, Italy, Female, business, Complication, Stem Cell Transplantation
Abstract

We analyzed the main modalities and clinical outcomes of the early discharge outpatient model in autologous stem cell transplantation (EDOM-ASCT) for multiple myeloma in Italy. EDOM-ASCT was employed in 382 patients, for a total of 522 procedures, between 1998 and 2012. Our study showed high homogeneity among centers in terms of inclusion criteria, supportive care, and in hospital readmission criteria. Overall, readmissions during the aplastic phase occurred in 98 of 522 transplantations (18.8%). The major extrahematological complication was neutropenic fever in 161 cases (30.8%), which required readmission in 76 cases. The incidence of severe World Health Organization grade 3 to 4 mucositis was 9.6%. By univariate analysis, fever, mucositis, altered renal function at diagnosis, second transplantation, and transplantation performed late in the course of the disease were significantly correlated with readmission, whereas fever, mucositis, altered renal function, and timing of transplantation remained the only independent predictors by multivariate analysis. Overall, transplantation-related mortality was 1.0%. No center effect was observed in this study (P = .36). The safety and low rate of readmission of the EDOM-ASCT in myeloma trial suggest that this strategy could be extended to other transplantation centers if a stringent patient selection and appropriate management are applied. (C) 2014 American Society for Blood and Marrow Transplantation.

Published
2014

39. Multi-center experience using total lymphoid irradiation and anti-thymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B., RISITANO, ANTONIO MARIA, Messina, G, Giaccone, L, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Ar, Schianca, Fc, Pini, M, Risitano, ANTONIO MARIA, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, M, Montanari, M, Console, G, Boccadoro, M, Ricardi, U, and Bruno, B.

Published
2012

40. Reduced-intensity allogeneic stem cell transplantation is an effective salvage strategy for relapsed/refractory peripheral T-cell non-Hodgkin lymphomas

Author

Corradini P, Dodero A, Narni F, Fanin R, Matteucci P, Scime R, Farina L, Carniti C, Rambaldi A, Bonifazi F, Di Bartolomeo P, Olivieri A, Benedetti F, Console G, Angelucci E, Gianni AM, Tarella C., CICERI , FABIO, Corradini, P, Dodero, A, Narni, F, Fanin, R, Matteucci, P, Ciceri, Fabio, Scime, R, Farina, L, Carniti, C, Rambaldi, A, Bonifazi, F, Di Bartolomeo, P, Olivieri, A, Benedetti, F, Console, G, Angelucci, E, Gianni, Am, and Tarella, C.

Published
2007

41. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT

Author

Cattina, F., Skert, C., Bernardi, S., Malagola, Michele, Ottaviani, E., Bochicchio, M. T., Iacobucci, I., Soverini, S., Bonifazi, F., Bandini, G., Arpinati, M., Motta, M. R., Toffoletti, E., Damiani, D., Santoro, A., Fabbiano, F., Pastore, D., Specchia, G., Console, G., Bruno, M., Carella, G., Malagoli, A., Guadagnuolo, V., De Benedittis, C., Bergonzi, C., Fili, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, Simone, DI PALMA, Andrea, Martinelli, G., and Russo, Domenico

Published
2014

42. MULTI-GENOTYPE OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) TO STUDY GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECTS IN ALLOGENEIC STEM CELL TRANSPLANTATION

Author

Cattina, F., Skert, C., Bernardi, S., Ottaviani, E., Bochicchio, M., Iacobucci, I., Soverini, S., Bonifazi, F., Arpinati, M., Motta, M., Toffoletti, E., Damiani, D., Armando Santoro, Fabbiano, F., Pastore, D., Specchia, G., Console, G., Martino, B., Guadagnuolo, V., Benedittis, C., Malagola, M., Bergonzi, C., Fili, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, S., Di Palma, A., Martinelli, G., and Russo, D.

Published
2013

43. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies

Author

Messina, G, Giaccone, Luisa, Festuccia, M, Irrera, G, Scortechini, I, Sorasio, R, Gigli, F, Passera, R, Cavattoni, I, Filippi, Andrea Riccardo, Schianca, Fc, Pini, M, Risitano, Am, Selleri, C, Levis, A, Mordini, N, Gallamini, A, Pastano, R, Casini, M, Aglietta, Massimo, Montanari, M, Console, G, Boccadoro, Mario, Ricardi, Umberto, Bruno, Benedetto, and Gruppo Italiano Trapianti di Midollo

Subjects
Male, Myeloid, Transplantation Conditioning, Graft vs Host Disease, total lymphoid irradiation, antithymocyte globulin, bone marrow transplantation, Graft-versus-host disease, Gastroenterology, Severity of Illness Index, HLA Antigens, Recurrence, Nonmyeloablative conditioning, biology, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, surgical procedures, operative, medicine.anatomical_structure, Hematologic Neoplasms, Histocompatibility, Cyclosporine, Female, Whole-Body Irradiation, Total lymphoid irradiation/antithymocyte globulin, Adult, medicine.medical_specialty, Globulin, anti-thymocyte globulin, Refractory, Antigen, Internal medicine, medicine, Humans, Transplantation, Homologous, hematological malignancies, Aged, Antilymphocyte Serum, Transplantation, business.industry, Mycophenolic Acid, medicine.disease, Survival Analysis, Anti-thymocyte globulin, Surgery, biology.protein, business
Abstract

A non myeloablative conditioning with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) was shown to protect against graft-versus-host disease (GVHD). To evaluate the effects of TLI-ATG in a multicenter study, 45 heavily pretreated patients, median age 51, with lymphoid (n = 38) and myeloid (n = 7) malignancies were enrolled at 9 centers. Twenty-eight patients (62%) received at least 3 lines of treatment before allografting, and 13 (29%) had refractory/relapsed disease at the time of transplantation. Peripheral blood hematopoietic cells were from HLA identical sibling (n = 30), HLA-matched (n = 9), or 1 antigen HLA-mismatched (n = 6) unrelated donors. A cumulative TLI dose of 8 Gy was administered from day −11 through −1 with ATG at the dose of 1.5 mg/kg/day (from day −11 through −7). GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. Donor engraftment was reached in 95% of patients. Grade II to IV acute GVHD (aGVHD) developed in 6 patients (13.3%), and in 2 of these patients, it developed beyond day 100. Incidence of chronic GVHD (cGVHD) was 35.8%. One-year nonrelapse mortality was 9.1%. After a median follow-up of 28 months (range, 3-57 months) from transplantation, median overall survival was not reached, whereas median event-free survival was 20 months. This multicenter experience confirms that TLI-ATG protects against GVHD and maintains graft-vs-tumor effects.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results